$GPCR

Structure Therapeutics (GPCR) reported a 3.3% weight-loss signal in a Phase 1/2a trial of ACCG-2671. The study involved 31 healthy adults, with six participants receiving 10mg showing the mean reduction. The company is now testing daily and weekly regimens in an 84-day study, with results expected in 2027. Investors focus on sustained efficacy and tolerability, as gastrointestinal side effects were reported at higher doses.

Structure Therapeutics Inc. (GPCR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights First patients dosed in aleniglipron (oral small molecule GLP-1 receptor agonist) Phase 3 ACCOMPLISH program for chronic weight management Data from Phase 1 SAD clinical trial

Cantor Fitzgerald analyst Prakhar Agrawal reiterated a Buy on Structure Therapeutics (NASDAQ:GPCR) on June 7 and set a $101 price target. BMO Capital analyst Evan Seigerman reiterated Buy on June 5 with a $145 target, citing clinical-trial results for aleniglipron showing sustained weight loss and a favorable safety profile, plus effects on blood pressure and inflammation.

The article highlights three biotech takeover targets after AbbVie’s acquisition of Apogee Therapeutics, citing Big Pharma’s patent-cliff pressure and demand for de-risked assets. It names Revolution Medicines (Phase 3 RASolute 302: median OS 13.2 vs 6.7 months; shares ~$169.51; mkt cap ~$36B), Structure Therapeutics (oral GLP-1 aleniglipron Phase 2: ~16% weight loss; cash ~$1.5B; mkt cap ~$3.2B), and Legend Biotech (Carvykti revenue $1.03B FY2025; Q1 2026 $305.1M; shares $29.30; target $57.59).

Structure Therapeutics Inc. (GPCR) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001888886 True 0001888886 2026-06-17 2026-06-17 0001888886 gpcr:AmericanDepositarySharesAdssEachRepresentingThreeOrdinarySharesParValue0.0001PerOrdinaryShareMember 2026-06-17 2026-06-17 0001888886 gpcr:OrdinarySharesParValue0.0001PerShareMember 2026-06-17 2026-06-17 iso421

Polymarket traders and analysts are focusing on Viking Therapeutics (VKTX) as an obesity M&A target, citing an estimated 38.5% implied acquisition probability before 2027. The company has no revenue and a ~$3.59B market cap; shares closed at $30.89 on May 22, 2026. Analysts’ mean target is $92.33. Viking’s oral VK2735 showed up to 12.2% weight loss at 13 weeks, and Phase 3 VANQUISH-1 is fully enrolled with 4,500+ patients. Potential buyers mentioned include Eli Lilly, Pfizer, and Novo Nordisk.

William Blair and Leerink Partners both maintained an "Outperform" rating on Structure Therapeutics (GPCR) on March 16, 2026, citing strong conviction in the company's oral GLP-1 program, aleniglipron. Despite modest intraday share declines, analysts emphasized the considerable market opportunity and clinical differentiation, without issuing new price targets. Investors are advised to view these ratings as affirmation of potential rather than immediate buy signals, awaiting further clinical readouts and commercialization details.

Structure Therapeutics (GPCR) saw its stock rise by approximately 8% following the release of positive topline phase 2 data for its oral GLP-1 receptor agonist, leniglipron, indicated for obesity. The promising results were derived from the 44-week ACCESS II study and interim data from another ongoing study.

Structure Therapeutics Inc. announced the closing of an upsized public offering, raising approximately $747.5 million from the sale of American depositary shares (ADSs) and pre-funded warrants. The offering included the full exercise of the underwriters' option to purchase additional ADSs. This significant capital infusion will support the company's work in developing novel oral small molecule therapeutics.

Novo Nordisk faces headwinds and leadership shifts, while Structure Therapeutics eyes pivotal obesity-drug data later this year.